Pyelonephritis – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Pyelonephritis – Pipeline Review, H2 2017’, provides an overview of the Pyelonephritis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pyelonephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pyelonephritis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Pyelonephritis

The report reviews pipeline therapeutics for Pyelonephritis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Pyelonephritis therapeutics and enlists all their major and minor projects

The report assesses Pyelonephritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Pyelonephritis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Pyelonephritis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Pyelonephritis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Achaogen Inc

AstraZeneca Plc

Meiji Seika Pharma Co Ltd

Merck & Co Inc

MerLion Pharmaceuticals Pte Ltd

The Medicines Company

Zavante Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Pyelonephritis - Overview

Pyelonephritis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Pyelonephritis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Pyelonephritis - Companies Involved in Therapeutics Development

Achaogen Inc

AstraZeneca Plc

Meiji Seika Pharma Co Ltd

Merck & Co Inc

MerLion Pharmaceuticals Pte Ltd

The Medicines Company

Zavante Therapeutics Inc

Pyelonephritis - Drug Profiles

(avibactam + ceftazidime) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(ceftolozane sulfate + tazobactam sodium) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(meropenem + vaborbactam) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AAI-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

finafloxacin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fosfomycin tromethamine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nacubactam - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

plazomicin sulfate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pyelonephritis - Dormant Projects

Pyelonephritis - Discontinued Products

Pyelonephritis - Product Development Milestones

Featured News & Press Releases

Jun 05, 2017: Achaogen Highlights Data Demonstrating Potential of Plazomicin Against MDR Gram-Negative Bacteria at ASM Microbe 2017 Annual Meeting

Apr 17, 2017: The Medicines Company to Present Data at ECCMID 2017 on Infectious Disease Portfolio Including Investigational Antibiotic Meropenem-Vaborbactam

Jan 30, 2017: FDA Approves Allergan's sNDA for AVYCAZ (ceftazidime and avibactam) to include new Phase III data in Patients with Complicated Urinary Tract Infections, Including Pyelonephritis

Oct 26, 2016: Merck Highlights Data Presentation on ZERBAXA at ID Week 2016

Oct 11, 2016: FDA Accepts Supplemental New Drug Application (sNDA) for AVYCAZ (ceftazidime and avibactam)

Jun 28, 2016: New antibiotic Zavicefta approved in the European Union for patients with serious bacterial infections

Jun 15, 2016: Merck Presents Data on ZERBAXA (ceftolozane and tazobactam) at ASM Microbe 2016

Jun 02, 2016: Achaogen Awarded $20 Million Contract Option by BARDA to Support Development of Plazomicin for Multi-Drug Resistant Gram-Negative Infections

Jun 02, 2016: Achaogen Reaches 50 Percent Patient Enrollment in Phase 3 EPIC Registration Trial of Plazomicin

Apr 07, 2016: Merck To Present Data on ZERBAXA at ECCMID 2016

Feb 22, 2016: New Antibiotic Against Drug-Resistant Bacteria Now Available

Jul 23, 2015: Zerbaxa receives positive CHMP opinion for complicated intra-abdominal infections

Feb 25, 2015: Actavis Receives U.S. FDA Approval for AVYCAZ (CEFTAZIDIME-AVIBACTAM)

Jun 18, 2014: MerLion completes recruitment in Finafloxacin phase II cUTI trial

Aug 22, 2013: FDA Grants Qualified Infectious Disease Product Designation and Fast Track Status for MerLion Pharma’s Lead Antibacterial Candidate Finafloxacin

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Pyelonephritis, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pyelonephritis – Pipeline by Achaogen Inc, H2 2017

Pyelonephritis – Pipeline by AstraZeneca Plc, H2 2017

Pyelonephritis – Pipeline by Meiji Seika Pharma Co Ltd, H2 2017

Pyelonephritis – Pipeline by Merck & Co Inc, H2 2017

Pyelonephritis – Pipeline by MerLion Pharmaceuticals Pte Ltd, H2 2017

Pyelonephritis – Pipeline by The Medicines Company, H2 2017

Pyelonephritis – Pipeline by Zavante Therapeutics Inc, H2 2017

Pyelonephritis – Dormant Projects, H2 2017

Pyelonephritis – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Pyelonephritis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports